Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 50 Shares of Stock

by · The Cerbat Gem

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) Director Jan Malcolm sold 50 shares of the stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $482.98, for a total transaction of $24,149.00. Following the completion of the transaction, the director directly owned 470 shares in the company, valued at approximately $227,000.60. This represents a 9.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Up 1.1%

Shares of United Therapeutics stock traded up $5.48 during trading on Friday, reaching $493.99. The company’s stock had a trading volume of 638,832 shares, compared to its average volume of 578,838. The business’s 50-day moving average price is $456.99 and its 200-day moving average price is $372.72. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $496.73. The firm has a market cap of $21.27 billion, a PE ratio of 18.72, a P/E/G ratio of 4.81 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.39 earnings per share. Equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on UTHR. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. HC Wainwright raised their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Wells Fargo & Company lifted their price target on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. UBS Group boosted their price target on United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Finally, Morgan Stanley set a $447.00 price objective on United Therapeutics in a research note on Wednesday, October 29th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $505.00.

Check Out Our Latest Analysis on United Therapeutics

Institutional Trading of United Therapeutics

Hedge funds have recently made changes to their positions in the company. Allworth Financial LP raised its holdings in United Therapeutics by 26.1% in the 3rd quarter. Allworth Financial LP now owns 449 shares of the biotechnology company’s stock valued at $188,000 after buying an additional 93 shares during the last quarter. Cambria Investment Management L.P. grew its holdings in United Therapeutics by 20.9% during the 3rd quarter. Cambria Investment Management L.P. now owns 2,657 shares of the biotechnology company’s stock worth $1,114,000 after acquiring an additional 460 shares during the last quarter. CIBC Private Wealth Group LLC increased its position in United Therapeutics by 66.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 713 shares of the biotechnology company’s stock valued at $299,000 after acquiring an additional 284 shares during the period. CIBC Bancorp USA Inc. acquired a new position in United Therapeutics in the 3rd quarter valued at approximately $644,000. Finally, Wilmington Savings Fund Society FSB raised its stake in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Further Reading